These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28465315)

  • 1. A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome.
    Sweet DG; Turner MA; Straňák Z; Plavka R; Clarke P; Stenson BJ; Singer D; Goelz R; Fabbri L; Varoli G; Piccinno A; Santoro D; Speer CP
    Arch Dis Child Fetal Neonatal Ed; 2017 Nov; 102(6):F497-F503. PubMed ID: 28465315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial.
    Ramanathan R; Biniwale M; Sekar K; Hanna N; Golombek S; Bhatia J; Naylor M; Fabbri L; Varoli G; Santoro D; Del Buono D; Piccinno A; Dammann CE
    J Pediatr; 2020 Oct; 225():90-96.e1. PubMed ID: 32553868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Natural versus Synthetic Surfactant with SP-B and SP-C Analogs in a Porcine Model of Meconium Aspiration Syndrome.
    Salvesen B; Curstedt T; Mollnes TE; Saugstad OD
    Neonatology; 2014; 105(2):128-35. PubMed ID: 24356240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.
    Ricci F; Murgia X; Razzetti R; Pelizzi N; Salomone F
    Pediatr Res; 2017 Feb; 81(2):369-375. PubMed ID: 27973472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of synthetic surfactant CHF5633 with SP-B and SP-C analogues on lung function and inflammation in rabbit model of acute respiratory distress syndrome.
    Mikolka P; Curstedt T; Feinstein R; Larsson A; Grendar M; Rising A; Johansson J
    Physiol Rep; 2021 Jan; 9(1):e14700. PubMed ID: 33403805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral and lung effects of a new generation synthetic surfactant with SP-B and SP-C analogs in preterm lambs.
    Rey-Santano C; Mielgo VE; Murgia X; Gomez-Solaetxe MA; Salomone F; Bianco F; Pelizzi N; Loureiro B; López de Heredia Y Goya J
    Pediatr Pulmonol; 2017 Jul; 52(7):929-938. PubMed ID: 28221717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Synthetic Surfactant CHF5633 Restores Lung Function and Lung Architecture in Severe Acute Respiratory Distress Syndrome in Adult Rabbits.
    Mikolka P; Kosutova P; Kolomaznik M; Nemcova N; Hanusrichterova J; Curstedt T; Johansson J; Calkovska A
    Lung; 2024 Jun; 202(3):299-315. PubMed ID: 38684519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome: two-year outcomes.
    Sweet DG; Turner M; Straňák Z; Plavka R; Clarke P; Stenson B; Singer D; Goelz R; Fabbri L; Varoli G; Piccinno A; Santoro D; Del Buono D; Speer CP
    J Matern Fetal Neonatal Med; 2022 Dec; 35(24):4739-4742. PubMed ID: 33345663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
    Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
    Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung.
    Sato A; Ikegami M
    PLoS One; 2012; 7(7):e39392. PubMed ID: 22808033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new generation synthetic reconstituted surfactant CHF5633 suppresses LPS-induced cytokine responses in human neonatal monocytes.
    Glaser K; Fehrholz M; Papsdorf M; Curstedt T; Kunzmann S; Speer CP
    Cytokine; 2016 Oct; 86():119-123. PubMed ID: 27505451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the New Generation Reconstituted Surfactant CHF5633 on Human CD4+ Lymphocytes.
    Fehrholz M; Glaser K; Seidenspinner S; Ottensmeier B; Curstedt T; Speer CP; Kunzmann S
    PLoS One; 2016; 11(4):e0153578. PubMed ID: 27077658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
    Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
    J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention and treatment of respiratory distress syndrome in premature infants using intratracheally administered surfactants].
    de Winter JP; Egberts J; de Kleine MJ; van Bel F; Wijnands JB; Guit GL
    Ned Tijdschr Geneeskd; 1992 Oct; 136(41):2018-24. PubMed ID: 1407193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
    Lamboley-Gilmert G; Lacaze-Masmonteil T;
    Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A; Allen R; Doros G; O'Brien S
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the New Generation Synthetic Reconstituted Surfactant CHF5633 on Pro- and Anti-Inflammatory Cytokine Expression in Native and LPS-Stimulated Adult CD14+ Monocytes.
    Glaser K; Fehrholz M; Curstedt T; Kunzmann S; Speer CP
    PLoS One; 2016; 11(1):e0146898. PubMed ID: 26790130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
    Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
    Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial.
    Hascoët JM; Picaud JC; Ligi I; Blanc T; Moreau F; Pinturier MF; Zupan V; Guilhoto I; Hamon IR; Alexandre C; Bouissou A; Storme L; Patkai J; Pomedio M; Rouabah M; Coletto L; Vieux R
    JAMA Pediatr; 2016 Apr; 170(4):365-72. PubMed ID: 26928567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.